Here is a very nice honor that Dalton got 20 years ago that I either had forgotten or didn't know of it.
UNIVEC President and CEO David Dalton Selected as Honoree by Genetic Disease Foundation
Share Article
Univec, Inc. announced that President and CEO Dr. David L. Dalton was selected to be honored by the Genetic Disease Foundation for his involvement with the organization and the pharmaceutical industry to treat and prevent genetic diseases.
(PRWEB) APRIL 14, 2002
FARMINGDALE, N.Y. - April 12, 2002 - Farmingdale-based Univec, Inc., (OTCBB:UNVC - news) today announced that President and CEO Dr. David L. Dalton was selected to be honored at the Genetic Disease Foundation's Gala on June 5, 2002 at Chelsea Piers in New York City. Dr. Dalton is being honored for his involvement with the organization and the pharmaceutical industry to treat and prevent genetic diseases such as Sickle Cell Anemia.
The Genetic Disease Foundation (GDF) was established in 1997 by various organizations, patients and families who had a common goal of supporting research and education to combat genetic disease. The foundation's primary mission is to fight and prevent all genetic diseases collectively, rather than concentrate on one specific type. GDF has designated the Department of Human Genetics at the Mount Sinai School of Medicine to focus on discovering the causative genes for rare and common diseases and on developing new methods for their prevention and cure.
Dr. David L. Dalton, President and CEO of Univec, stated that, "It is an honor to be recognized by the Genetic Disease Foundation and share in their commitment to help prevent the spread of disease." Dr. Dalton is also the founder and majority owner of Pharmacy Services, Inc., a certified Minority Business Enterprise that fulfills pharmaceutical and medical supply requirements for government entities, such as correctional institutions, clinics and other healthcare facilities.
About Univec
Founded in 1992, Univec is considered one of the leading innovators in the design and production of auto-disable and safety syringes. The Company also provides safe delivery of physician samples and disposal of infectious medical waste. The Company has production facilities in Portugal, South Korea, China, Belgium and the U.S., and distributes its products in 80 countries.
Forward Looking Statements
This document contains forward-looking statements based on current expectations that could be affected by the risks and uncertainties involved in Univec's business. These risks and uncertainties include, but are not limited to, the risks described from time to time in Univec's reports to the Securities and Exchange Commission, which include Univec's Annual Report on Form 10-K. Subsequent written or oral statements attributable to Univec or persons acting on its behalf are expressly qualified in their entirety by the cautionary statements in this document and those in Univec's reports filed with the SEC.
Contact:
G. Edward Kalbaugh
Allegent Growth Strategies International
516-364-7034 or e-mail gekalbaugh@allegentgsi.com
https://www.prweb.com/releases/2002/04/prweb36831.htm
UNIVEC President and CEO David Dalton Selected as Honoree by Genetic Disease Foundation
Share Article
Univec, Inc. announced that President and CEO Dr. David L. Dalton was selected to be honored by the Genetic Disease Foundation for his involvement with the organization and the pharmaceutical industry to treat and prevent genetic diseases.
(PRWEB) APRIL 14, 2002
FARMINGDALE, N.Y. - April 12, 2002 - Farmingdale-based Univec, Inc., (OTCBB:UNVC - news) today announced that President and CEO Dr. David L. Dalton was selected to be honored at the Genetic Disease Foundation's Gala on June 5, 2002 at Chelsea Piers in New York City. Dr. Dalton is being honored for his involvement with the organization and the pharmaceutical industry to treat and prevent genetic diseases such as Sickle Cell Anemia.
The Genetic Disease Foundation (GDF) was established in 1997 by various organizations, patients and families who had a common goal of supporting research and education to combat genetic disease. The foundation's primary mission is to fight and prevent all genetic diseases collectively, rather than concentrate on one specific type. GDF has designated the Department of Human Genetics at the Mount Sinai School of Medicine to focus on discovering the causative genes for rare and common diseases and on developing new methods for their prevention and cure.
Dr. David L. Dalton, President and CEO of Univec, stated that, "It is an honor to be recognized by the Genetic Disease Foundation and share in their commitment to help prevent the spread of disease." Dr. Dalton is also the founder and majority owner of Pharmacy Services, Inc., a certified Minority Business Enterprise that fulfills pharmaceutical and medical supply requirements for government entities, such as correctional institutions, clinics and other healthcare facilities.
About Univec
Founded in 1992, Univec is considered one of the leading innovators in the design and production of auto-disable and safety syringes. The Company also provides safe delivery of physician samples and disposal of infectious medical waste. The Company has production facilities in Portugal, South Korea, China, Belgium and the U.S., and distributes its products in 80 countries.
Forward Looking Statements
This document contains forward-looking statements based on current expectations that could be affected by the risks and uncertainties involved in Univec's business. These risks and uncertainties include, but are not limited to, the risks described from time to time in Univec's reports to the Securities and Exchange Commission, which include Univec's Annual Report on Form 10-K. Subsequent written or oral statements attributable to Univec or persons acting on its behalf are expressly qualified in their entirety by the cautionary statements in this document and those in Univec's reports filed with the SEC.
Contact:
G. Edward Kalbaugh
Allegent Growth Strategies International
516-364-7034 or e-mail gekalbaugh@allegentgsi.com
https://www.prweb.com/releases/2002/04/prweb36831.htm
2
